LDC Beteiligungen

Overview

LDC Beteiligungen is a German venture capital firm specializing in early-stage investments in the life sciences sector. The firm focuses on transforming promising academic research into innovative pharmaceutical leads and antibodies, advancing them to initial proof-of-concept in animal models and candidate nomination. LDC collaborates closely with high-profile partners from research and industry to build a strong portfolio of small molecule and antibody leads with exceptional medical and commercial potential. Established in 2008 by Max Planck Innovation, LDC operates as an independent enterprise with an entrepreneurial outlook, positioned as a translational research center specialized in small molecule drug discovery. The firm offers a comprehensive range of drug discovery services, from target identification to lead optimization, adhering to the highest industry standards. LDC's business model has been validated through successful licensing agreements, such as the one with Bayer Schering Pharma AG, granting exclusive rights to a novel kinase inhibitor compound developed by LDC. LDC's strategic approach involves sustaining long-term partnerships with the Max Planck Society and its institutes, as well as forming alliances with various pharmaceutical companies and research institutions. This collaborative model enables LDC to effectively bridge the gap between academic research and commercial drug development, contributing significantly to the advancement of new therapies for diseases with high medical need.

Investment Focus

• Focus on early-stage life sciences projects with high medical and commercial potential
• Collaborative partnerships with academic institutions and industry leaders
• Advancement of drug candidates to initial proof-of-concept in animal models

Portfolio Companies